ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

“One Time Offer” On Comprehensiveness Approved By NCAB

September 22, 1989

In Brief: Oncology Nurse Rumored For NCAB; Rosenberg To Give Karofsky Lecture; Fundraiser’s $$ Short

December 14, 1990

DCPC Board Okays Core Grant Changes On Shared Resources

January 30, 1987

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

DCPC Advisers Ok Four New Grant Programs To Foster Prevention

May 22, 1992

CCRAC Members Say Practicing Physicians Do Not Use Cancer Prevention Methods

August 24, 1979